Autor: |
Krishan R. Jethwa, MD, Christopher D. Hellekson, MD, Jaden D. Evans, MD, William S. Harmsen, MS, Tyler J. Wilhite, MD, Thomas J. Whitaker, PhD, Sean S. Park, MD PhD, C. Richard Choo, MD, Bradley J. Stish, MD, Kenneth R. Olivier, MD, Rimki Haloi, MBBS, Val J. Lowe, MD, Brian T. Welch, MD, J. Fernando Quevedo, MD, Lance A. Mynderse, MD, R.Jeffrey Karnes, MD, Eugene D. Kwon, MD, Brian J. Davis, MD PhD |
Jazyk: |
angličtina |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
Advances in Radiation Oncology, Vol 4, Iss 4, Pp 659-667 (2019) |
Druh dokumentu: |
article |
ISSN: |
2452-1094 |
DOI: |
10.1016/j.adro.2019.06.006 |
Popis: |
Purpose: To assess gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) of 11C-choline-positron emission tomography (CholPET) guided lymph node (LN) radiation therapy (RT) in patients who experience biochemical failure after radical prostatectomy. Methods and Materials: From 2013 to 2016, 107 patients experienced biochemical failure of prostate cancer, had CholPET-detected pelvic and/or paraortic LN recurrence, and were referred for RT. Patients received androgen suppression and CholPET guided LN RT (median dose, 45 Gy) with a simultaneous integrated boost to CholPET-avid sites (median dose, 56.25 Gy), all in 25 fractions. RT-naïve patients had the prostatic fossa included in the initial treatment volumes followed by a sequential boost (median dose, 68 Gy). GI and GU AEs were reported per Common Terminology Criteria for Adverse Events (version 4.0) with data gathered retrospectively. Differences in maximum GI and GU AEs at baseline, immediately post-RT, and at early (median, 4 months) and late (median, 14 months) follow-up were assessed. Results: Median follow-up was 16 months (interquartile range [IQR], 11-25). Median prostate-specific antigen at time of positive CholPET was 2.3 ng/mL (IQR, 1.3-4.8), with a median of 2 (IQR, 1-4) choline-avid LNs per patient. Most recurrences were within the pelvis (53%) or pelvis + paraortic (40%). Baseline rates of grade 1 to 2 GI AEs were 8.4% compared with 51.9% (4.7% grade 2) of patients post-RT (P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|